Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review
Jacobs J, Binns T, Schlafer D, Woo J, Booth G, Adkins B. Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review. Transfusion And Apheresis Science 2025, 64: 104081. PMID: 39883995, DOI: 10.1016/j.transci.2025.104081.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraSecondary thrombotic thrombocytopenic purpuraFood and Drug Administration Adverse Event Reporting SystemAssociated with alemtuzumabThrombocytopenic purpuraMultiple sclerosisReport of thrombotic thrombocytopenic purpuraImmune-mediated thrombotic thrombocytopenic purpuraCongenital thrombotic thrombocytopenic purpuraHematopoietic stem cell transplantationFAERS databaseAnd Drug Administration Adverse Event Reporting SystemStem cell transplantationUnited States Food and Drug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemADAMTS13 deficiencyAlemtuzumab administrationCell transplantationADAMTS13 geneEvent Reporting SystemPatient demographicsAlemtuzumabCase reportTherapy indicationsCross-sectional analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply